



Overview of Gastric Cancer malignancies landscape in Asia



Contents

1. CLINICAL LANDSCAPE IN ASIA-PACIFIC	3
EPIDEMIOLOGY AND CLINICAL ACTIVITY	3
KEY OPINION LEADERS IN GASTRIC CANCER	4
2. RECRUITMENT AND DATA FROM NOVOTECH NETWORK	5
3. NOVOTECH OVERVIEW.....	6
REGISTERED PRODUCT EXPERIENCE	7
NOVOTECH PEOPLE EXPERTISE AND EXPERIENCE	7

Confidentiality notice: This proposal and its contents are confidential and proprietary to Novotech and are supplied to the party above for consideration of the proposal. This proposal may contain privileged, confidential or trade secret information that is protected from disclosure by law.


1. Clinical landscape in Asia-Pacific

Epidemiology and clinical activity

Gastric Cancer malignancies are highly prevalent in Asia, especially in South Korea and in Japan where the prevalence rate is about 10 times higher than in Western countries.

Diet and lifestyle such as alcohol consumption, smoking and obesity, as well as other factors such as *Helicobacter pylori* infections, are known to increase the risk of developing Gastric Cancer and explain the high rates of cases observed in Asia.

Prevalence rate of Gastric Cancer malignancies (per 100,000) in a selection of Western and Asian countries




Countries in which Novotech directly operates

Source: IPD

Biopharma companies initiated 282 trials in Gastric Cancer between 2015 and 2017, about 57 % of which (161/282) involved a country from Asia. China, Taiwan and South Korea were the most frequently involved countries.

Top 10 countries in Asia Pacific in relation to the number of Gastric Cancer studies initiated by Biopharma companies between 2015 and 2017



Countries in which Novotech directly operates

Source: clinicaltrials.gov

Key opinion leaders in Gastric Cancer

Prof. YUNG-JUE BANG

Seoul National University Hospital – SOUTH KOREA

Prof. Bang is Professor of Medical Oncology, President of Biomedical Research Institute and Director of Clinical Trials Center of Seoul National University Hospital. He is the co-author of over 300 publications including in *The Lancet* and *The New England Journal of Medicine*. He was involved in over 130 clinical studies including 63 in Gastric Cancer for Merck, AstraZeneca, Eli Lilly, Curis, Five Prime Therapeutics, Roche and MacroGenics. Prof. Bang is the Chief Scientific Officer of In2Gen.



Dr. LIN SHEN

Beijing Cancer Hospital & Peking University – CHINA

Dr. Shen is Vice President of Clinical Oncology, Beijing Cancer Hospital & Peking University, China, and Deputy Director at Beijing Institute for Cancer Research. Dr. Shen is the co-author of over 100 scientific publications. Dr. Shen specifically worked on 42 Gastric Cancer trials and was involved in 133 clinical studies for Hutchison MediPharma, Qilu Pharmaceutical Co., Roche, Innovent Biologics, RemeGen, and CStone Pharmaceuticals.

Prof. YOON-KOO KANG

ASAN Medical Center – SOUTH KOREA

Prof. Kang is Assistant Professor at UUCM AMC and a Research Fellow in Medicine Branch from the National Cancer Institute. Prof. Kang is one of the most active clinical investigators in South Korea. He is the co-author of over 200 scientific publications and was involved in over 150 clinical studies, including 50 studies in Gastric Cancer for EMD, Merck, Bukwang and Sanofi.



Prof. LI-TZONG CHEN

National Institute of Cancer Research - TAIWAN

Prof. Chen is Associate Professor, Internal Medicine, and Attending Physician in Gastroenterology, Kaohsiung Medical University, Taiwan. Prof. Chen is the co-author of over 200 publications and was involved in 60 clinical studies, including over 10 in Gastric Cancer for BMS, AGITG, and Bayer.

Prof WINNIE YEO

Prince of Wales Hospital - HONG KONG

Prof. Yeo is Co-director of the Comprehensive Cancer Trials Unit of the Chinese University of Hong Kong. She serves as a member and advisor in various expert panels and committees in the Hong Kong Hospital Authority. Prof. Yeo is the co-author of over 100 publications and involved in 43 clinical studies, including 5 in Gastric Cancer for BMS, and Roche.



Source: PUBMED; CITELINE


2. Recruitment and data from Novotech network

Information collected through various study feasibility assessments confirmed the great interest from several investigators to engage in Gastric Cancer trials.

As expected based on the epidemiology landscape, sites in South Korea have the highest number of patients with Gastric Cancer (around 280 patients per year depending on the site). A significant number of patients were also reported from sites in Thailand (around 100 patients per year) and Hong Kong (around 90 patients per year).

The standard of care for many of these patients, relies on treatment with *ECX*, *Folfox*. (1st line), *Gemcitabine* (2nd line), and *Xeloda* (3rd line). The table on the right displays the average number of Advanced / metastatic Gastric Cancer patients treated annually by a sample of Asia-based clinical investigators (n=27).

Average number of Advanced / metastatic Gastric Cancer patients treated annually by a sample of Asia-based clinical investigators (n=27)



3. Novotech Overview

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in the Asia Pacific region. Novotech provides clinical development services across all therapeutic areas and has been instrumental in the success of hundreds of Phase I - IV clinical trials.



Full service CRO with on-the-ground operations in Australia, New Zealand, India, South Korea, Taiwan, Thailand, Malaysia and Singapore, the Philippines, Hong Kong and China.

340+ full-time employees

Best in class technology solutions including CTMS (Oracle Siebel), eDC (Medidata Rave, Oracle Inform), eTMF (Sure Clinical) and Safety (Oracle Argus)

Extensive therapeutic area experience handling clinical studies with biopharma companies across all phases of clinical trials

Managed APAC component of pivotal trials for multiple FDA, EMA registered products since 2001

Established in 1996, with head office in Sydney, Australia

Recipient of the 2017 Frost & Sullivan award for **Asia Pacific Biotech CRO Company of the Year**

Full service CRO



Services

Registered product experience


Novotech has successfully managed the APAC component of over 20 FDA and EMA registered compounds and devices. This speaks to the quality of the data generated from Novotech sites across the region and to our experience working on large pivotal studies for US and EU based biotech.

Abraxane (breast, lung, and pancreatic cancer)	Nerlynx (HER2-positive breast cancer)
Cellegesic (hemorrhoids)	Northera (orthostatic hypertension)
Depodur (post-operative pain)	Ocaliva (primary biliary cirrhosis)
Firazyr (hereditary angioedema)	Solaraze (actinic and solar keratosis)
Galafold (Fabry's disease)	Tarceva (NSCLC and pancreatic cancer)
GC Flu H5N1 Multi Injection (influenza)	Vimpat (partial-onset seizures)
Hismanal (allergic rhinitis)	Xiaflex (Dupuytren's and Peyronie's contracture)
Istodax (T-cell lymphomas)	Xtandi (prostate cancer)
Levact (chronic lymphocytic leukemia)	Zilretta (osteoarthritic knee pain)
Lucentis (wet AMD)	Zurampic (gout)
Metvix PDT (skin cancer)	Zytiga (prostate cancer)

Novotech people expertise and experience

Novotech has many of the most experienced professionals in the industry.

Average years of Novotech staff experience





NOVOTECH

The Asia Pacific CRO